Galenica’s US partner Luitpold Pharmaceuticals has submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Injectafer, used to treat iron deficiency anaemia.

Injectafer is a non-dextran intravenous iron (i.v.) replacement therapy containing ferric carboxymaltose as its active pharmaceutical ingredient.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The submission includes the data from two randomised controlled clinical trials which assessed the cardiovascular risk profile of Injectafer.

One trial compares Injectafer to Venofer (iron sucrose injection) in patients with iron deficiency anaemia and chronic kidney disease, while the second study compares Injectafer to either oral or intravenous (i.v.) iron in patients with iron deficiency anaemia of various etiologies.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact